Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
Decrypt
Read Full Article at Decrypt →
Ad Slot — In-Article (728x90)
A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4. 8 billion.
This is a summary. For the full story, read the original article at Decrypt.
Original source: Decrypt